Ecnoglutide: what it is and what the evidence says
A GLP-1 analogue engineered with a bias towards cyclic AMP signalling, in an attempt to separate the metabolic effect from part of the adverse effects.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
Metabolism is not a single lever. Talk about metabolic compounds usually collapses three separate mechanisms into one word. Appetite regulation is one. How well cells respond to insulin is another, and largely independent of the first. Mobilising stored fat is a third. A compound may act on one and leave the other two untouched, so knowing which one is the difference between understanding a molecule and reciting its name.
What it is studied for
Weight management, type 2 diabetes.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
A long-acting GLP-1 analogue with real and orderly human evidence: phase 2 in type 2 diabetes (2024), phase 3 in overweight or obesity (2025), and the phase 3 EECOH-1 and EECOH-2 trials.
The limitation that matters most
Clinical development has been carried out almost entirely in China, so extrapolation to other populations is limited; long-term cardiovascular data do not yet exist.
Regulatory status
Approved in China (NMPA). Not approved by the FDA or the EMA.
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
Approved in China only. No long-term cardiovascular data.
Speak with a healthcare professional if you are already on diabetes medication or have a history of digestive or gallbladder problems, since GLP-1 drugs slow gastric emptying.
What this page cannot give you
A reference page can take you this far. You know what Ecnoglutide is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a diploma with a verifiable folio, a record to track how you progress, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialhuman Lancet Diabetes Endocrinol · 2025 · PMID 40555243 →
- Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trialhuman Lancet Diabetes Endocrinol · 2025 · PMID 40854315 →
- Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trialhuman Nat Commun · 2026 · PMID 41501026 →
- Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trialhuman Nat Commun · 2024 · PMID 39333121 →
- Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analogpreclinical Mol Metab · 2023 · PMID 37364710 →
- Ecnoglutide: First Approvalsreview Drugs · 2026 · PMID 42412371 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Ecnoglutide or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is Ecnoglutide?
A GLP-1 analogue engineered with a bias towards cyclic AMP signalling, in an attempt to separate the metabolic effect from part of the adverse effects. It is studied within the area of metabolic.
Is there human evidence for Ecnoglutide?
A long-acting GLP-1 analogue with real and orderly human evidence: phase 2 in type 2 diabetes (2024), phase 3 in overweight or obesity (2025), and the phase 3 EECOH-1 and EECOH-2 trials.
Is it approved by any health agency?
Approved in China (NMPA). Not approved by the FDA or the EMA.
What is the dose of Ecnoglutide?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what Ecnoglutide is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.